Paranta Biosciences is seeking expressions of interest from drug development and pharmaceutical companies to partner in the development of follistatin therapies for the following conditions:

  •     Organ Transplantation
  • Paranta Biosciences is offering a special licensing/partnering opportunity for the use of their follistatin biotherapeutic as a novel and effective agent in organ preservation solutions. Follistatin targets inflammation by modulating a key cytokine, activin A (as well as other TGF-beta superfamily members). As an additive to organ preservation media, follistatin is efficacious at reducing ischemia-reperfusion injury as evidenced in our pre-clinical studies (click here to download information brochure).

  •     Cystic Fibrosis (CF)
  •     Chronic Obstructive Pulmonary Disease (COPD)
  •     Chronic Bronchitis
  •     Influenza
  •     Asthma
  •     Liver Fibrosis / Cirrhosis
  •     Sepsis / Septicemia
  •     Cachexia
  •     Idiopathic Pulmonary Fibrosis (IPF)

For further information on partnering, collaboration and licensing opportunities, please contact the company’s CEO on:

T +61 (3) 9526 0021

Leave a Reply